Corporate Europe Observatory

Exposing the power of corporate lobbying in the EU

  • Dansk
  • NL
  • EN
  • FI
  • FR
  • DE
  • EL
  • IT
  • NO
  • PL
  • PT
  • RO
  • SL
  • ES
  • SV

Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health

A new report released today reveals the dramatic extent of the pharmaceutical industry's lobbying efforts towards EU decision-makers, with the industry spending an estimated 15 times more than civil society actors working on public health or access to medicines.

'Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health' by Corporate Europe Observatory probes the privileged access to decision-making in Brussels enjoyed by the sector and facilitated by a lobby spend of around €40 million, extensive meetings with policy-makers, and presence in advisory groups. Under-reporting and the continued avoidance by some of the EU's voluntary lobby transparency system mean that overall industry spending may be much higher than the transparency register reveals.

The report shows that Big Pharma enjoys a staggering number of meetings with European Commission departments and officials. For example, influential EU pharmaceutical trade association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), had over 50 meetings with the Juncker Commission in its first four and a half months of office.

The study examines some of Big Pharma’s channels of influence in the EU and exposes concrete examples of EU law and policies that have been targeted or shaped by the industry. These include rules around clinical trials’ data transparency, trade secrets, and the negotiation of the EU-US trade deal, the Transatlantic Trade and Investment Partnership (TTIP).

It also puts pharma lobby group EFPIA in the spotlight, examining its goals, tactics, access and influence, including a critique of the EU’s multi-billion euro public-private partnership with EFPIA, the ‘Innovative Medicines Initiative’.

Report: http://corporateeurope.org/sites/default/files/20150904_bigpharma_web.pdf

'Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health' by Corporate Europe Observatory probes the privileged access to decision-making in Brussels enjoyed by the sector and facilitated by a lobby spend of around €40 million, extensive meetings with policy-makers, and presence in advisory groups. Under-reporting and the continued avoidance by some of the EU's voluntary lobby transparency system mean that overall industry spending may be much higher than the transparency register reveals.The report shows that Big Pharma enjoys a staggering number of meetings with European Commission departments and officials. For example, influential EU pharmaceutical trade association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), had over 50 meetings with the Juncker Commission in its first four and a half months of office.The study examines some of Big Pharma’s channels of influence in the EU and exposes concrete examples of EU law and policies that have been targeted or shaped by the industry. These include rules around clinical trials’ data transparency, trade secrets, and the negotiation of the EU-US trade deal, the Transatlantic Trade and Investment Partnership (TTIP).It also puts pharma lobby group EFPIA in the spotlight, examining its goals, tactics, access and influence, including a critique of the EU’s multi-billion euro public-private partnership with EFPIA, the ‘Innovative Medicines Initiative’.Report: http://corporateeurope.org/sites/default/files/20150904_bigpharma_web.pdf
 

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Following the high-level appointment of former European Commission President José Manuel Barroso to Goldman Sachs, NGOs have launched a petition demanding stricter rules for ex-EU commissioners’ revolving door moves.

Corporate Europe Observatory, Friends of the Earth and LobbyControl today wrote to Martin Schulz, President of the European Parliament, calling on him to investigate Angelika Nieber MEP over a possible conflict of interest.

CEO presents some first reflections on the UK's vote for Brexit.

Think tanks work all around the institutions of the European Union but how they work and who they work for is often less clear. Our new report offers a closer look at these supposedly impartial hubs of expertise and highlights how the think-tank status has become a convenient vehicle for corporate lobbying activities.

A few weeks after the May coup against Dilma Rousseff by conservative parties backed by the country's largest corporations, Brazil's “interim” government, led by Michel Temer, signed an emergency loan to the State of Rio de Janeiro to help finance infrastructure for the 2016 Olympics. The bailout was conditional to selling off the State's public water supply and sanitation company, the Companhia Estadual de Águas e Esgotos (Cedae). 

When we interviewed City Councillor and chair of Rio’s Special Committee on the Water Crisis Renato Cinco, in December 2015, he was already warning against such privatisation threats and provided important background information on the water situation in Rio.

Never before has a former European Commission official been criticised as much for his post-EU career as ex-Commission president Barroso upon joining infamous US investment bank Goldman Sachs this summer. Citizens are outraged and evidence already points towards a gross violation of the EU Treaty.

Following the high-level appointment of former European Commission President José Manuel Barroso to Goldman Sachs, NGOs have launched a petition demanding stricter rules for ex-EU commissioners’ revolving door moves.

Corporate Europe Observatory's new report 'A spoonful of sugar' illustrates how the sugar lobby undermines existing laws and fights off much-needed measures that are vital for tackling Europe’s looming obesity crisis.

 
 
 
 
 
-- placeholder --
 
 
 

The corporate lobby tour